# Bacterial and host determinants of progression, manifestations and consequences of TB

> **NIH NIH U19** · RBHS-NEW JERSEY MEDICAL SCHOOL · 2021 · $391,945

## Abstract

ABSTRACT - PROJECT 1
Historically, TB has been characterized as a two-stage process – infection and disease. It now is clear that
infection and importantly the likelihood once infected of progressing to TB is heterogeneous and varies with
time. We propose now to address in human studies how bacterial and host heterogeneity modify the
distribution of stages of TB infection following close contact with a TB case, the risk of progression and the
manifestations and sequelae of TB disease. On the bacterial side, Mtb strains from index cases could be
dichotomized into high transmission (Mtb-HT) and low transmission (Mtb-LT) based on the proportion of
exposed household contacts that were TST+. Mtb-HT was associated with greater risk of progression to
disease and more cavitation on chest X-ray. As regards host heterogeneity, we posit that risk of signature
signatures are a proxy for intrinsic differences in the host immune response to Mtb. In South Africa the ACS-
COR signature was a good correlate of PET-CT scan findings of subclinical TB. As regards short-and long-
term risk of progression, in Brazil, we characterized a transcriptional signature PREDICT29 tied to the immune
response that predicted progression to TB. We will use the household contact model in a prospective cohort in
Uganda and retrospective cohorts in Uganda and Brazil to partition the risk of infection with Mtb-HT between
immunopathology of the index case (eg cavitation and subsequent lung damage), greater force of infection for
HHC, the modifying effects of PREDICT29 and co-morbidities, and increased risk of progression along the
spectrum from LTBI to TB. Specific Aims are to determine the impact of Mtb strain phenotype (eg Mtb-HT v
Mtb-LT) and host heterogeneity (risk of progression signatures, co-morbidities) on: 1. The distribution of stages
of Mtb infection and disease in exposed HHC: the proportion of MTBI that express PREDICT29, a risk of
progression signature; ACS-COR, an inflammatory signature; subclinical TB and active TB; 2. The risk and
timing of progression from MTBI to TB and 3. The extent and nature (eg cavitation) of pulmonary disease in
TB index cases; the duration of inflammation; and the consequent impairment in pulmonary function.
These studies could permit individualized approaches to diagnosis, targeting of preventive therapy, and
treatment of active TB. They synergize with Project 2 and the clinical core in providing PBMC and BAL from
well-characterized populations that will allow determination of the immunologic basis for the findings in this
Project 1; and with Projects 3 in providing clinical Mtb isolates known to differ in transmission and pathogenesis
for study of tolerance.

## Key facts

- **NIH application ID:** 10271648
- **Project number:** 1U19AI162598-01
- **Recipient organization:** RBHS-NEW JERSEY MEDICAL SCHOOL
- **Principal Investigator:** Jerrold J. Ellner
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $391,945
- **Award type:** 1
- **Project period:** 2021-09-23 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10271648

## Citation

> US National Institutes of Health, RePORTER application 10271648, Bacterial and host determinants of progression, manifestations and consequences of TB (1U19AI162598-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10271648. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*